Impact of preexisting virus-specific maternal antibodies on cytomegalovirus population genetics in a monkey model of congenital transmission

Short title: Preexisting antibodies and CMV diversity

Diana Vera Cruz[1], Cody S Nelson[2], Dollnovan Tran[3], Peter A Barry[4], Amitinder Kaur[3], Katia Koelle[5], Sallie R Permar[2]*

[1]Computational Biology and Bioinformatics program / Duke Center for Genomic and Computational Biology, Duke University, and [2]Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA. [3]Tulane National Primate Research Center, Tulane University, Covington, Louisiana, USA. [4]Center for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis, California, USA. [5]Department of Biology, Emory University, Atlanta, Georgia, USA.

* Address correspondence to Sallie R. Permar (sallie.permar@duke.edu)

Abstract

Human cytomegalovirus (HCMV) infection is the leading non-genetic cause of congenital birth defects worldwide. While several studies have investigated the genetic composition of viral populations in newborns diagnosed with HCMV, little is known regarding mother-to-child viral transmission dynamics and how therapeutic interventions may impact within-host viral populations. Here, we investigate how preexisting CMV-specific antibodies shape the maternal viral population and intrauterine virus transmission. Specifically, we characterize the genetic composition of CMV populations in a monkey model of congenital CMV infection to examine the effects of passively-infused hyperimmune globulin (HIG) on viral population genetics in both maternal and fetal compartments. In this study, 11 seronegative, pregnant monkeys were challenged with rhesus CMV (RhCMV), including a group pretreated with a standard potency HIG preparation (n = 3), a group pretreated with a high-neutralizing potency HIG preparation (n = 3), and an untreated control group (n = 5). Targeted amplicon deep sequencing of RhCMV glycoprotein *B* and *L* genes revealed that one of the three strains present in the viral inoculum (UCD52) dominated maternal and fetal viral populations. We identified *de novo* minor haplotypes of this strain and characterized their dynamics. Many of the identified haplotypes were consistently detected at multiple timepoints within sampled maternal tissues, as well as across tissue compartments, indicating haplotype persistence over time and transmission between maternal compartments. However, haplotype numbers and diversity levels were not appreciably different across HIG pretreatment groups. We found that while the presence of maternal antibodies reduced viral load and congenital infection, it has no apparent impact in the intrahost viral genetic diversity at the investigated loci. Interestingly, some haplotypes present in fetal and maternal-fetal interface tissues were also identified in maternal samples of corresponding dams, providing evidence for a wide RhCMV mother-to-fetus transmission bottleneck even in the presence of preexisting antibodies.

Author summary

Human cytomegalovirus (CMV) is the most common infectious cause of birth defects worldwide. Knowledge gaps remain regarding how maternal immunity impacts the genetic composition of CMV populations and the incidence of congenital virus transmission. Addressing these gaps is important to inform vaccine development efforts. Using viral samples collected from a monkey model of congenital CMV infection, we investigated the impact of passively-administered maternal antibodies on the genetic composition of the maternal virus population and that transmitted to the fetus. Our analysis focused on two CMV genes that encode glycoproteins that facilitate viral cellular entry and are known epitope targets of the humoral immune response. By identifying and analyzing variants across sampled maternal tissues, we found no impact in CMV genetic diversity by preexisting CMV-specific antibodies, despite the observation that such antibodies reduce viral load and confer some protection against congenital transmission. We further found that some minor variants identified in fetal and maternal-fetal interface tissues were also present in corresponding maternal tissues, indicating that a large number of viral particles passed from dam to fetus in observed cases of congenital transmission.

60 **Introduction**

61 Human cytomegalovirus (HCMV) is a member of the β-herpesvirus family and a ubiquitous
62 pathogen that establishes lifelong infection in its host. Seroprevalence rates for HCMV range from
63 45% in developed nations to 100% in developing nations [1]. While initial HCMV infection is
64 typically asymptomatic in the setting of intact host immunity, congenitally infected infants,
65 immune-compromised individuals, and transplant recipients can suffer adverse HCMV-related
66 outcomes [2–4]. Indeed, HCMV is the leading infectious cause of congenital birth defects, with
67 approximately 1 in 150 live-born infants worldwide infected with HCMV, from which at least 10-
68 20% will develop long-term sequelae including sensorineural hearing loss, microcephaly, and
69 cognitive impairment [2].

70 Congenital CMV infection during pregnancy can result from either primary infection or viral
71 reactivation and/or superinfection (secondary infection). While congenital infection could be
72 seeded from the maternal genital tract [5,6], most cases of transmission are thought to occur from
73 mother to fetus through maternal blood flow to the placenta [7,8]. High levels of maternal HCMV
74 viremia and maternal infection earlier during gestation have been correlated with a greater risk of
75 congenital infection and more severe congenital disease [9,10]. Following congenital infection,
76 HCMV can be disseminated throughout the developing fetus with HCMV detectable in multiple
77 fetal tissues in almost 50% of cases [11].

78 Recent HCMV whole-genome sequencing has revealed that the virus exhibits remarkable
79 genetic diversity both within and between hosts [12–15] despite being a DNA virus. While it is
80 hypothesized that mixed infections and strain recombination are key factors contributing to
81 observed within-host viral diversity [14–16], *de novo* point mutations may also play a role in the
82 generation of intrahost variation. Single nucleotide polymorphisms are distributed unevenly
83 across the viral genome, with more variable regions found within immune evasion-related genes
84 and coding sequences for multiple envelope glycoproteins [15]. Within a single host, these diverse
85 HCMV populations have been observed to change dynamically over time and differ genetically

86 across tissues [12,15,17,18]. Existing studies report the presence of low-frequency intrahost
87 variants following HCMV infection in solid organ transplant recipients and congenital CMV cases
88 [12,17]. Furthermore, a longitudinal study has shown evidence for persistence of these minor
89 variants over time [12]. And while genetic diversity within a single compartment appears stable
90 over time [13], viral populations from different compartments of a single host can be as genetically-
91 distinct as populations between hosts [13]. Further, viral genomes obtained from the same
92 anatomical compartment across different hosts have been found to show characteristic genetic
93 similarities [15], suggesting that tissue-specific adaptations likely occur and contribute to
94 anatomical compartmentalization.

95 One of the challenges of HCMV research is that herpesviruses are highly species-specific
96 [19], which has led to a reliance on human clinical trials [7]. Yet, congenital virus transmission can
97 be modeled using both guinea pigs and nonhuman primate models [7,20]. In particular, rhesus
98 macaques and rhesus CMV (RhCMV) are a highly-relevant model for understanding adult/fetal
99 HCMV pathogenesis [21,22] and congenital infection [9,23], as RhCMV is the closest
100 cytomegalovirus species to HCMV [19,24] and the physiology/immunology of rhesus monkey
101 pregnancy is highly analogous to humans [21]. Previously, our group demonstrated that the
102 depletion of $CD4^+$ T cells followed by intravenous RhCMV inoculation of seronegative pregnant
103 monkeys resulted in consistent RhCMV congenital infection and a high rate of fetal loss [24]. We
104 subsequently tested the impact of preexisting antibodies on the incidence and severity of
105 congenital CMV transmission in this monkey model via passive infusion of hyperimmune globulin
106 (HIG) prior to RhCMV inoculation. This study established that preexisting RhCMV-specific
107 antibodies ("standard-potency" HIG) can prevent fetal loss in the absence of functional CD4+ T
108 cell immunity and that highly-neutralizing antibodies ("high-potency" HIG) may block congenital
109 transmission altogether [9]. Furthermore, this previous work demonstrated that potently-
110 neutralizing antibodies present at the time of primary infection can alter viral dynamics *in vivo* [9].

111 In this study, we focus on the impact of HIG pretreatment on the genetic composition of
112 RhCMV populations found across maternal and fetal tissue compartments. Our analysis is based
113 on RhCMV sequence data derived from maternal compartment samples (plasma, saliva, and
114 urine), samples from the maternal-fetal interface (amniotic fluid and placenta), and fetal tissue
115 samples (fetal heart, brain, lungs, kidney and spleen), where available. Due to the large genome
116 size of RhCMV and a desire to identify viral haplotypes, we focused our approach on amplicon
117 sequencing of variable regions of antibody-targeted glycoprotein genes *gB* and *gL* to explore the
118 effects of preexisting antibodies on viral evolution and tissue compartmentalization. Our work
119 contributes to the deeper understanding of maternal and congenital infection dynamics to better
120 inform developing therapeutic interventions to prevent congenital CMV transmission.
121

122 **Methods**

123

124 *Study setting.*

125 Eleven pregnant RhCMV-seronegative dam monkeys were intravenously inoculated with
126 RhCMV to investigate the ability of preexisting antibodies to inhibit congenital CMV transmission.
127 The study consisted of three groups of monkeys: a control group that received no hyperimmune
128 globulin (HIG) pretreatment and two HIG pretreatment groups that differed in their HIG regimen.
129 The first ("standard") HIG pretreatment group consisted of 3 dams, each of which received a
130 single dose of a standard HIG preparation given 1 hour prior to viral inoculation. The second
131 ("high-potency") group consisted of 3 dams, each of which received an initial dose 1 hour prior to
132 viral inoculation and a second dose 3 days later. Both doses in the high-potency group used a
133 high-potency HIG preparation by screening serum donor monkeys for serum RhCMV neutralizing
134 activity, as described in [9]. The control group consisted of 5 dams**,** 3 of which were historical
135 controls [23]. The RhCMV inoculum was a mixture of three different strains: UCD52, UCD59, and
136 180.92, at relative frequencies of 25%, 25%, and 50% (by infectious viral titer), respectively.
137 These strains are known to have different tropism *in vitro*, with 180.92 isolated on rhesus
138 fibroblasts [25,26], and UCD52/UCD59 isolated on epithelial cells [27].

139 For each of the 11 dams studied, samples were taken from maternal blood plasma, urine,
140 saliva, and amniotic fluid at multiple time points following infection. Sample availability varied
141 across dams for reasons such as early fetal loss or low sample volume, previously described in
142 [9]. A subset of the available samples had virus populations that were successfully sequenced
143 and form the basis of our analysis **(Table S1)**. The remainder of these samples did not have
144 successful viral sequencing due to either low viral loads or inadequate sample quality prior to
145 library construction. In addition, virus populations in placental tissue samples from one control
146 group monkey and two standard pretreatment group monkeys, as well as tissue samples from

147 one congenitally infected fetus (from a standard pretreatment group dam) were successfully
148 sequenced **(Table S2)**.
149 RhCMV viral load was quantified from each sample using qPCR, as described in [9]. For
150 all samples, multiple viral load measurements (3 to 18) were taken to ensure that samples with
151 relatively low levels of virus present were identified as being positive for RhCMV. Viral load on
152 the log10 scale was calculated as the mean of the individual log10 viral load sample
153 measurements. When viral load was below the limit of detection (100 viral copies per ml for
154 plasma and amniotic fluid and 100 viral copies per total DNA µg for urine and saliva), we set its
155 value to half of the detection limit.
156

157 *Animal study ethics statement.*

158 The animal protocol titled "Maternal immune correlates with protection against congenital
159 cytomegalovirus transmission in rhesus monkeys" was approved by the Tulane University and
160 the Duke University Medical Center Institutional Animal Care and Use Committees (IACUC) under
161 the protocol numbers P0285 and A186-15-06, respectively. Indian-origin rhesus macaques were
162 housed at the Tulane National Primate Research Center and maintained in accordance with
163 institutional and federal guidelines for the care and use of laboratory animals, specifically the
164 USDA Animal Welfare regulations, PHS Policy on Humane Care and Use of Laboratory
165 Animals[28], the NIH/NRC Guide for the Care and Use of Laboratory Animals, Association for
166 Assessment and Accreditation of Laboratory Animal Care accreditation guidelines, as well as
167 Tulane University and Duke University IACUC care and use policies. Tulane National Primate
168 Research Center has strict policies to minimize pain and distress. The monkeys were observed
169 on a daily basis and were administered tiletamine/zolazepam (Telazol), or ketamine if they
170 showed signs of discomfort, pain or distress. In case of illness, the protocol involved analgesics
171 administration and supplemental nutritional support and/or fluid therapy as needed.

172 Housing conditions were determined by the time and type of RhCMV inoculation, aiming
173 to avoid horizontal transmission of RhCMV from other colony members, where RhCMV is
174 endemic. RhCMV-seronegative pregnant macaques were housed in pairs after RhCMV
175 inoculation if inoculated concurrently with the same viral isolate. Otherwise, single housing in BL2
176 containment facilities was required. The monkeys were maintained in a standard environment
177 enrichment setting which included manipulable items, swings, food supplements (fruit,
178 vegetables, treats), task-oriented feeding methods as well as human interaction with caretakers
179 and research staff. Dams were released into the colony after 2 or 3 weeks following C-section.

180 Anesthesia was considered for all procedures considered to cause more than slight pain
181 in humans, including routine sample collection. The agents used included: ketamine, butorphanol,
182 Telazol, buprenorphine, carprofen, meloxicam, and midazolam as needed. The criteria for end-

183 point was defined as loss of 25% of body weight from maximum body weight during protocol,
184 major organ failure or medical conditions unresponsive to treatment and surgical complications
185 unresponsive to immediate intervention. Policies stated that animals deemed at endpoint would
186 be euthanized by overdose of pentobarbital under the direction of the attending veterinarian,
187 consistent with the recommendations of the American Veterinary Medical Association guidelines
188 on euthanasia.
189
190 *PCR amplification, viral sequencing. and analysis pipeline.*
191 We PCR-amplified two variable regions within the genes encoding RhCMV glycoprotein
192 *B* (gB) and glycoprotein *L (gL)* of RhCMV for next-generation sequencing. The *gB* amplicon was
193 408 nucleotides long and *gL* amplicon 399 nucleotides long, primer sequences for each amplicon
194 can be found in [9]. Since the RhCMV inoculum consisted of three different strains (UCD52,
195 UCD59, and 180.92), we previously confirmed the absence of primer bias against these strains
196 [9] For each of a given sample's two amplified loci, our goal was to process two technical
197 replicates. Several samples, however, only had a single successfully sequenced replicate, while
198 other samples had more than two successfully sequenced replicates (**Table S1, S2**). As described
199 previously [9], each replicate sample was independently PCR-amplified and sequenced following
200 library preparation. Replicates from samples with low viral load were amplified using a nested
201 PCR approach. All replicates were sequenced on an Illumina MiSeq platform, using paired end
202 reads of 300 bases.
203 To identify viral haplotypes and quantify their frequencies, we first used PEAR [29] to
204 reconstruct (for each available technical replicate) the targeted locus by merging the paired-end
205 reads corresponding to each sequenced fragment. The fused reads were then filtered using the
206 *extractor* tool from the SeekDeep pipeline [30], which filters sequences according to their length,
207 overall quality scores, and presence of primer sequences. Haplotype reconstruction for a given
208 technical replicate was performed on the filtered sequences using the *qluster* tool from SeekDeep,

209 which performs an iterative process of removing spurious, low abundance sequence groups by
210 adding them to more abundant, genetically similar sequence groups when the genetic mismatch
211 between groups occurs at nucleotide positions with low quality.

212 To obtain a set of haplotypes and their frequencies for a given sample, we combined
213 identified haplotypes across technical replicates. Specifically, for a haplotype to be considered
214 present in a sample, we required it to be detected in both sample replicates. Haplotypes that did
215 not meet this criterion were merged with their genetically-closest haplotype in the sample, and
216 the count of this genetically closest haplotype in the sample was increased accordingly. When
217 only a single replicate was available, we could not perform this step and therefore kept all
218 identified haplotypes present in the single available replicate. When more than two technical
219 replicates were available, we restricted our analyses to the two replicates that were the most
220 similar to one another genetically, based on correlation of haplotype frequencies (see below).

221

222 *Quality assurance and error reduction in sequencing data*

223 We performed additional tests and required additional criteria to be met to ensure the
224 quality of each sample that would undergo subsequent analysis. First, to reduce the number of
225 spurious haplotypes in a given sample, we set a frequency threshold that sample haplotypes were
226 required to exceed. This threshold was established as 0.436% based on analysis of plasmid
227 controls. Specifically, we constructed two synthetic plasmids, one containing the *gB* gene and the
228 other containing the *gL* gene. Two technical replicates from each plasmid were sequenced using
229 the same protocol as for the RhCMV samples. Because a single haplotype should be present in
230 these plasmid control populations, any shared low-frequency haplotype is likely a product of PCR
231 amplification error or sequencing error. We found 19 minor haplotypes in the *gB* plasmid control
232 sample after merging technical replicates. These haplotypes ranged in frequency from 0.01% to
233 0.59% (**Figure S1**). We found 29 minor haplotypes in the *gL* plasmid control sample after merging
234 technical replicates. These haplotypes ranged in frequency from 0.03% to 0.42% (**Figure S1**).

235 Our chosen frequency threshold of 0.436% was set at the 0.95 quantile of the combined minor
236 haplotype distributions from the *gB* and *gL* plasmids.

237 As a second quality assurance step, we performed chimera detection on the haplotypes
238 in each merged sample. A haplotype was classified as a chimera if there was a combination of
239 partial alignments to two observed (and higher frequency) haplotypes in the same sample.
240 Detected chimeras were discarded. These chimeras contributed to only a small fraction of the
241 total reads in each sample (ranging from 1.95% to 7.82% of the reads across all samples).

242 As a third quality assurance step, we restricted our analysis to those samples that had a
243 Pearson correlation score exceeding 0.70 between the frequencies of the shared haplotypes
244 across technical replicates on the log10 scale. For those samples with only a single technical
245 replicate, we could not perform this step and instead included the sample in our analysis only if
246 the read count exceeded 5000.

247 **Table S1** shows the final set of maternal tissue and amniotic fluid samples that were
248 included in our analyses, for both the *gB* and the *gL* loci. **Table S2** shows the set of samples from
249 the maternal-fetal interface (other than the amniotic fluid samples) and from fetal samples that
250 were included in our analyses. In addition to these samples, the genetic composition of the
251 inoculum was analyzed. Each of the three viral stocks comprising the inoculum (UCD52, UCD59,
252 180.92) was independently sequenced. Two successfully sequenced replicates were available
253 for each of the three stock samples.

254

255 *Strain classification and nucleotide diversity calculations.*

256 Each identified haplotype in a sample was classified as belonging to one of the three
257 strains that comprised the inoculum (UCD52, UCD59, or 180.92) based on its genetic distance to
258 the reference sequences of these three strains. The reference sequences of the targeted *gB* and
259 *gL* regions were obtained from [27] for strains UCD52 and UCD59 and from [26]. for strain 180.92.
260 Nucleotide diversity π present in a sample was calculated for each strain independently using the

261 commonly used Nei-Gojobori equation, as described in [31]. All identified haplotypes, across all
262 sequenced samples, are listed in the **Appendix S3 and Appendix S4**. The frequencies of these
263 haplotypes in each of the sequenced samples, including the inoculum, are given in the **Appendix**
264 **S1 and Appendix S2**.
265
266 *Statistical analysis and software*
267 Data processing, analysis, and visualization were performed in R. Pairwise comparisons
268 between groups were performed using non-parametric tests as indicated. For the network
269 visualization of haplotypes, we employed the R package *RCy3* version 1.2.0 that interfaces R 3.4
270 with Cytoscape.
271
272 *Data and code availability*
273 Sequencing data in fastq format from all the samples is available in SRA under the Bioproject
274 PRJNA386504. Primer sequences for the gB and gL regions can be found in [9]. All the R codes
275 required for this study are available on GitHub: dverac/SNAPP.

276 **Results**

277 *Maternal viral load dynamics, congenital transmission, and strain dominance.*

278 As previously described [9], dams in the high-potency HIG pretreatment group had
279 reduced peak viral loads in maternal plasma relative to dams in the control group following primary
280 maternal infection (**Figure S2A**). Viral kinetics in the saliva and urine were also delayed in the
281 high-potency pretreatment group compared to the control group (**Figure S2C,D**) [9]. Interestingly,
282 and as previously noted [9], only dams with a peak plasma viral load exceeding 5.0 $\log_{10}$ viral
283 copies/mL transmitted the virus to the amniotic fluid compartment. This included all 5 dams in the
284 control group, 2 out of 3 dams in the standard pretreatment group, but none of the 3 dams in the
285 high-potency pretreatment group. Viral dynamics in the amniotic fluid, when present, did not
286 appear to differ between the control group monkeys and the standard HIG pretreatment group
287 monkeys (**Figure S2B**).

288 Of the three viral strains used in the RhCMV inoculum, UCD52 became dominant in the
289 overwhelming majority of tissue compartments, regardless of pretreatment group status (**Figure**
290 **S3**) [9]. The single exception to this, which was supported by both the *gB* and *gL* loci, was a week
291 1 plasma sample from a dam from the control group (C1) in which UCD59 haplotypes were the
292 most abundant. Given the dominance of the UCD52 strain in the overwhelming majority of
293 samples, we focused our remaining analyses on haplotypes that were classified as belonging to
294 the dominant UC52 strain.

295

296 *Minor RhCMV haplotypes and levels of genetic diversity during acute maternal infection.*

297 Across the majority of analyzed samples, we found that the dominant *in vivo* UCD52
298 haplotype was the canonical UCD52 reference haplotype of the viral inoculum. This was the case
299 both for the *gB* locus and the *gL* locus, and across all groups and compartments studied.

300 Our analysis of amplified sequences from the *gB* locus identified a large number of minor
301 haplotypes in maternal and fetal compartments that differed from the canonical UCD52 *gB*

302 haplotype by typically only a single nucleotide (**Figure 1**, **Figures S4-S11**). These minor
303 haplotypes ranged in frequency from just above the sequencing error cut-off frequency of 0.436%
304 up to 43.27%, with a median frequency of 0.80%. Maternal samples differed in the number of
305 identified *gB* haplotypes they contained, ranging from 1 to 33, with a median of 5 haplotypes per
306 sample. The number of haplotypes identified in a sample was not positively correlated with the
307 sample's viral load (**Figure S12**), indicating that the numbers of observed haplotypes were not
308 restricted by sample viral load. Given our constrained cut-off for haplotypes detection, these minor
309 haplotypes are potentially produced *de novo* as RhCMV spreads within each monkey. Within
310 individual dams, we observed that some of the minor haplotypes were shared across timepoints
311 from the same compartment and/or across compartments (**Figure 1**, **Figures S4-S11**). This
312 finding indicates that some of these minor haplotypes persist over a timespan of weeks in a given
313 compartment and that some of these minor haplotypes are likely transmitted across anatomic
314 compartments. Of the minor haplotypes that were shared across compartments, most were
315 shared between the plasma and one other compartment (**Figure 1**, **Figure 2**, **Figures S4-S11**).
316 This pattern may reflect plasma being a source of viral haplotypes for other compartments;
317 alternatively, it may simply be due to a larger number of plasma samples being successfully
318 sequenced relative to those from other compartments (**Table S1**). Interestingly, in 6 out of the 8
319 monkeys that had both urine and saliva sequences available, there were also minor *gB*
320 haplotypes that appeared to be shared exclusively between urine and saliva samples. These
321 haplotypes were generally found first in urine and then in a later week in the saliva, suggesting
322 potential oral auto-inoculation from virus shed in urine.

323 To assess whether the number of identified *gB* haplotypes differed by pretreatment group,
324 we calculated the median number of minor UCD52 haplotypes in each available tissue for each
325 of the 11 dams. We found no significant differences in the median number of minor *gB* haplotypes
326 by tissue across any pair of pretreatment groups (all Mann-Whitney *U* tests > 0.1; **Figure 3A**). To
327 determine whether certain tissues tended to allow more non-synonymous variation than other

328 tissues, or whether the extent of nonsynonymous variation differed by pretreatment group, we
329 further calculated the proportion of minor *gB* haplotypes that differed from the canonical haplotype
330 by a nonsynonymous mutation, by tissue and monkey. No major differences were found between
331 tissues or between pretreatment groups (for data on haplotypes, see **Appendix S1**).

332 The UCD52 haplotype patterns observed using the *gL* locus are consistent with those at
333 the *gB* locus. Specifically, minor *gL* haplotypes generally differed from one of the two dominant
334 *gL* haplotypes present in the inoculum by a single nucleotide (**Figure S13-S22**). Similar to the
335 frequencies observed for *gB* haplotypes, minor *gL* haplotypes were present at frequencies as low
336 as 0.44% and up to 48.16%, with a median frequency of 1.05%. Samples differed in the number
337 of identified *gL* haplotypes they contained, ranging from 2 to 29 with a median of 6 haplotypes per
338 sample. Again, no correlation was found between the number of haplotypes identified in a sample
339 and the sample's viral load (**Figure S23**). Some of the identified minor *gL* haplotypes appeared
340 to persist within the same tissue over time, and some were shared across tissue compartments.
341 Similar to our findings at the *gB* locus, most of the minor haplotypes that were shared across
342 compartments were shared between the plasma and one other compartment (**Figure S24**). Minor
343 *gL* haplotypes shared between urine and saliva compartments again suggested auto-inoculation.
344 Finally, consistent with the findings from the *gB* locus, the median number of *gL* minor haplotypes
345 observed in any tissue did not differ between pretreatment groups (**Figure 3**). We again found
346 no significant differences between tissues or pretreatment groups in the proportion of minor *gL*
347 haplotypes that were nonsynonymous (for data on haplotypes, see **Appendix S2**), consistent with
348 the lack of pattern at the *gB* locus.

349 We next assessed whether HIG pretreatment had an impact on RhCMV genetic diversity,
350 as measured by pairwise nucleotide diversity π for each sample's UCD52 viral population. Levels
351 of viral genetic diversity varied significantly between monkeys, compartments, and across weeks
352 (**Figure 4** for *gB*, **Figure S25** for *gL*). Despite this variation, median levels of *gB* viral genetic
353 diversity did not differ by pretreatment group for any tissue (all Mann-Whitney U tests > 0.1)

354 besides the amniotic fluid. In this compartment, median levels of *gB* viral genetic diversity
355 appeared to be slightly higher in standard pretreatment group monkeys than in control animals
356 (Mann-Whitney U test, p = 0.05). Median levels of *gL* viral genetic diversity did not differ by
357 pretreatment group for any tissue (all Mann-Whitney U tests > 0.1; **Figure S25**).
358
359 *Genetic diversity and compartmentalization of maternal RhCMV variants identified in placenta*
360 *and amniotic fluid*
361 We next sought to determine the extent to which minor UCD52 haplotypes were shared
362 between maternal compartments and compartments comprising the maternal-fetal interface
363 (amniotic fluid and placental tissues). As reported above, we found that some minor *gB* and *gL*
364 UCD52 haplotypes were shared between maternal plasma samples and amniotic fluid samples
365 (**Figures 1** and **2**; **Appendix S1** and **Appendix S2**). Similarly, some of the minor *gB* and *gL*
366 UCD52 haplotypes found in placental tissue samples were also present in maternal plasma
367 samples (**Figure 2**). Specifically, between placental tissues and plasma samples, we observed 6
368 shared minor *gL* haplotypes in C4 (**Figure S15**), 3 shared minor *gB* haplotypes in S2 (**Figure 1**),
369 1 shared minor *gL* haplotype in S2 (**Figure** S18), and 1 shared minor *gB* haplotype in S3 (**Figure**
370 S9). As these minor shared haplotypes are mostly present at marginal frequencies in maternal
371 tissues (median frequency in plasma for shared haplotypes: 1.28%, minimum 0.47%, in gB, S2;
372 maximum 24.05% in gL, S2) (**Appendix S1** and **Appendix S2**), the bottleneck between mother
373 and fetus is likely relatively large. Interestingly, we observed similar or larger number of minor *gB*
374 and *gL* UCD52 haplotypes in amniotic fluid samples compared to placental tissues (**Figure 2**,
375 **Figure S24**; **Appendix S1** and **Appendix S2**), indicating that *de novo* viral mutations may occur
376 in the fetus and subsequently be shed into the amniotic fluid. Interestingly, in the one case in
377 which placental plasma was available for analysis (dam S2 in **Figure 1**; **Figure S18**), we found
378 considerably more minor haplotypes in both *gB* and *gL* gene regions in this sample compared

379 with placental tissue samples and many of these minor haplotypes were not observed in maternal
380 plasma samples.
381
382 *Genetic diversity and compartmentalization of fetal RhCMV variants.*
383 Congenital infection was confirmed in two of three dams in the standard pretreatment
384 group and in all five control dams. Yet, all five control dams experienced fetal loss within 2-3
385 weeks of maternal infection and fetal tissues were often not recovered. In standard pretreatment
386 group dam S3, nearly all the fetal tissues harvested at 6 weeks post-RhCMV infection tested
387 positive for RhCMV, including fetal lung, brain, kidney, spleen, heart, placenta, amniotic fluid, and
388 amniotic membrane. Similar to our observation in the maternal tissue compartments, a single
389 major UCD52 haplotype (the canonical reference haplotype) was present in all fetal tissue
390 samples. Multiple minor UCD52 haplotypes were also detected in these samples (**Figure S9**;
391 **Figure 5**). Intriguingly, a second, minor haplotype was found in each of the fetal tissues, present
392 at frequencies ≤1%. This haplotype was also observed in one of the paired dam's three amniotic
393 fluid samples (week 3, frequency of 0.8%), placenta (frequency of 0.85%), and in two of the paired
394 dam's plasma samples (at weeks 3 and 6; frequencies of 0.58% and 0.66%, respectively) (**Figure**
395 **5**). Of the remaining 21 minor UCD52 haplotypes in fetal tissues, 4 were also present in amniotic
396 fluid samples and 5 in plasma samples of paired dam S3 (**Figure 5**). Plasma haplotypes detected
397 as late as weeks 5 and 6 post-inoculation contribute to those shared haplotypes. In comparison
398 to the 10 minor haplotypes shared between fetal tissues and maternal plasma/amniotic fluid
399 samples from the paired dam S3, only 0-5 minor haplotypes were shared between the fetal tissues
400 and non-paired dams. We then calculated pairwise genetic diversity π from each available fetal
401 tissue. We observed lower diversity in the fetal tissues compared to that in both the amniotic fluid
402 (p = 0.025) and the plasma at late weeks post-infection (Weeks 4 to 6, p = 0.095). We further
403 observed higher diversity in the fetal tissues compared to that in plasma during the first three
404 weeks post-infection (Weeks 1 to 3, p = 0.024). These observations together suggest that the

405 maternal viral population contributes to the viral diversity in the fetus and that congenital
406 transmission may be subject to a wide and potentially continuous bottleneck, through which
407 various minor haplotypes present in maternal plasma or amniotic fluid can be transmitted to the
408 fetus.

409 **Discussion**

410 In this study, we characterized the population genetics of RhCMV in a nonhuman primate
411 model of congenital CMV transmission and quantified the impact of preexisting maternal virus-
412 specific antibodies on the viral population at the maternal-fetal interface. Unique aspects of this
413 study include serial sampling from multiple maternal compartments over the time period of an
414 acute RhCMV infection as well as the sequencing of RhCMV-infected tissues at the maternal-
415 fetal interface and, in one instance, from fetal tissues. We found that all maternal and fetal tissue
416 samples (excepting one) were dominated by UCD52. Furthermore, there was a trend towards
417 higher UCD52 haplotype frequencies in the plasma of high-potency pretreatment group monkeys
418 compared to those in the control group monkeys and standard pretreatment group monkeys. The
419 reason for the dominance of this singular strain across HIG pretreatment groups is unclear,
420 although it likely indicates that the UCD52 strain is more genetically fit for *in vivo* replication than
421 either of the co-inoculated variants UCD59 and 180.92. Given the dominance of UCD52 in all
422 groups and tissues, we focused subsequent analyses on characterizing the genetic variation of
423 this strain in available samples. In the majority of samples from maternal tissues, maternal-fetal
424 interface, and fetal tissues, the major *gB* and *gL* UCD52 variant detected was the canonical
425 UCD52 reference sequence. However, most samples also had low-frequency (minor) UCD52
426 haplotypes present, with some of these minor haplotypes persisting over time and occasionally
427 shared between sampled compartments.

428 In our analyses, despite high-potency pretreatment monkeys having significantly lower
429 peak viral loads compared to standard and control group monkeys, we found no strong evidence
430 for a relationship between HIG pretreatment and maternal plasma UCD52 haplotype number or
431 nucleotide diversity. Together, these results suggest that preexisting antibodies can reduce
432 overall viral load but do not appear to restrict replication of specific UCD52 viral variants or limit
433 viral diversity. We also found no significant differences in saliva or urine virus haplotype number
434 or nucleotide diversity between the three groups at either *gB* or *gL* loci. While we previously

435 assessed and reported lower *maximum* plasma viral diversity levels in monkeys pretreated with
436 HIG compared to the control group [9], here, we included a more in-depth analysis across
437 timepoints to report the *median* viral diversity levels across monkeys, and did not find any lasting
438 impact of preexisting antibodies on maternal viral diversity.

439 Our identification of shared, minor UCD52 haplotypes between maternal plasma samples,
440 amniotic fluid, placental tissue, and fetal tissues is consistent with previous studies investigating
441 the population genetics of HCMV in newborns [12,32], which together point towards a loose
442 vertical transmission bottleneck between mother and fetus. While previous studies have
443 estimated transmission bottleneck sizes for HCMV and other viruses, in this study we were unable
444 to quantify transmission bottleneck sizes between mother and fetus due to: 1) low levels of
445 haplotype diversity and 2) haplotype frequencies near the limit of detection. Nevertheless, based
446 on the identification of minor UCD52 haplotypes across maternal, maternal-fetal interface, and
447 fetal tissues, our analysis suggests that diversity in a given tissue is generated through a
448 combination of multiple viral haplotypes being passed to that compartment, along with *de novo*,
449 local generation of viral mutations.

450 Recently, Sackman and coauthors proposed a model for congenital human CMV (HCMV)
451 transmission that involves two successive transmission events: maternal virus infection of
452 placental tissues followed by continued transmission of the placental viral population to fetal
453 circulation [33]. This model is supported by observations of the sustained presence of HCMV in
454 the placenta and umbilical cord, which would potentially allow for transmission between placental
455 tissues and fetal tissues over a longer time interval [34]. Our results provide further support for
456 this proposed model. Specifically, in our analysis of fetal samples from dam S3, we identified
457 minor haplotypes in fetal tissues that were also present in maternal plasma (**Figure S9**).
458 Furthermore, we observed that multiple haplotypes in this dam's amniotic fluid were also observed
459 in maternal plasma and other maternal compartments. Since amniotic fluid haplotypes derive from

460 both intrauterine and fetal viral populations, this finding again provides support for a loose
461 transmission bottleneck from mother to fetus.

462 Our conclusions are limited by multiple factors. First, as is common for experimental
463 monkey challenge studies and particular to studies of a selective colony of RhCMV seronegative
464 breeding animals, we are limited by the small number of animals in each group and by sample
465 availability. PCR amplification failure further limited the number of samples available for analysis
466 (**Table S1**). Second, this study did not employ full genome sequencing, but instead sequenced
467 only two gene regions (*gB* and *gL*) to allow for studies of virus population in samples with low viral
468 load. Subsequently, any effect of antibody selection over the non-sequenced regions of gB and
469 gL or over other viral proteins will not be observed. Third, because RhCMV is a DNA virus with a
470 low mutation rate, our conclusions were limited by the low levels of genetic diversity observed in
471 the samples. We also used highly conservative haplotype-calling and error reduction methods to
472 ensure that the haplotypes we identified were not false positives. As a result, however, we likely
473 excluded many true haplotypes, which reduced the diversity levels we characterized and limited
474 our ability to make inferences regarding transmission bottleneck sizes. Finally, given that our
475 animal model of congenital CMV transmission involves maternal $CD4^+$ T cell depletion, which
476 results in consistent placental transmission, our results might not be applicable to
477 immunocompetent individuals.

478 Despite these limitations, however, we were able to conclude that minor haplotypes
479 persisted over time within single maternal tissue compartments and that these minor haplotypes
480 were occasionally shared between anatomic compartments. Moreover, there was not a strict
481 bottleneck for the viral major and minor haplotypes that appeared in placenta, amniotic fluid, and
482 fetal tissues. All these observations are consistent with those from human congenital CMV cases
483 [12,15,35–37]. Patterns of viral diversity within and across compartments, however, did not
484 appear to differ between HIG pretreatment groups. These findings indicate that, although potently-
485 neutralizing CMV-specific antibodies can effectively reduce viral population size and prevent

486 congenital transmission [9], preexisting HIG had limited impact on the genetic makeup of the
487 maternal RhCMV populations or transmitted variants. These findings are interesting given the
488 growing evidence that preexisting HCMV-specific antibodies can reduce the incidence and
489 severity of congenital HCMV [9,38–40] , perhaps suggesting a model wherein congenital virus
490 transmission is dependent upon the overall quantity of maternal systemically-circulating virus
491 rather than antibody selection of specific variants at the maternal-fetal interface. Further studies,
492 ideally starting with an inoculum containing higher levels of viral diversity, may be required to
493 provide a deeper understanding of the extent of antibody-mediated immune-pressure on CMV
494 populations, as well as the effect of antibodies on viral transmission dynamics across the
495 placenta. Results from these studies will be critical to more effectively anticipate the effect of CMV
496 vaccines and therapeutic interventions on congenital CMV transmission potential and the
497 propensity for this virus to evolutionarily circumvent these interventions.
498

499 **Author contributions**

500 A.K., K.K. and S.R.P. designed research; C.S.N., D.T. and D.V.C. performed research; D.V.C.
501 analyzed data; P.A.B. and K.K. contributed analytic tools/expertise/reagents; and D.V.C, C.S.N.,
502 K.K. and S.R.P. wrote the paper.
503

504 **Acknowledgements**

505 This work was supported by NIH/NICHD Director's New Innovator grant to S.R.P
506 (DP2HD075699), NIH/NIAID grants to S.R.P. and K.K. (R21AI136556), fellowship grant to C.S.N
507 (F30HD089577), and NIH P51 OD011104 to the Tulane National Primate Research Center. The
508 funders had no role in study design, data collection and interpretation, decision to publish, or the
509 preparation of this manuscript. The content is solely the responsibility of the authors and does not
510 necessarily represent the official views of the National Institutes of Health.
511

512 **References**

513 1. Cannon MJ, Schmidt D, Hyde TB. Review of cytomegalovirus seroprevalence and
514 demographic characteristics associated with infection. Rev Med Virol. 2010;20: 202–213.
515 doi:10.1002/rmv.655
516 2. Boppana SB, Ross SA, Fowler KB. Congenital Cytomegalovirus Infection: Clinical
517 Outcome. Clin Infect Dis. 2013;57: S178–S181. doi:10.1093/cid/cit629
518 3. Daikos GL, Pulido J, Kathpalia SB, Jackson GG. Intravenous and intraocular ganciclovir
519 for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. Br J
520 Ophthalmol. 1988;72: 521–524. doi:10.1136/bjo.72.7.521
521 4. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression
522 following solid organ transplantation. Transpl Infect Dis. 2009;11: 195–202.
523 doi:10.1111/j.1399-3062.2009.00372.x
524 5. Pereira L, Maidji E, McDonagh S, Tabata T. Insights into viral transmission at the uterine-
525 placental interface. Trends Microbiol. 2005;13: 164–174. doi:10.1016/j.tim.2005.02.009
526 6. Pereira L, Maidji E, McDonagh S, Genbacev O, Fisher S. Human cytomegalovirus
527 transmission from the uterus to the placenta correlates with the presence of pathogenic
528 bacteria and maternal immunity. J Virol. 2003;77: 13301–13314.
529 doi:10.1128/JVI.77.24.13301-13314.2003
530 7. Weisblum Y, Panet A, Haimov-Kochman R, Wolf DG. Models of vertical cytomegalovirus
531 (CMV) transmission and pathogenesis. Semin Immunopathol. 2014;36: 615–625.
532 doi:10.1007/s00281-014-0449-1
533 8. Revello MG, Gerna G. Pathogenesis and prenatal diagnosis of human cytomegalovirus
534 infection. J Clin Virol. 2004;29: 71–83. doi:10.1016/j.jcv.2003.09.012
535 9. Nelson CS, Cruz DV, Tran D, Bialas KM, Stamper L, Wu H, et al. Preexisting antibodies
536 can protect against congenital cytomegalovirus infection in monkeys. JCI Insight. 2017;2.
537 doi:10.1172/jci.insight.94002

538 10. Delforge M-L, Costa E, Brancart F, Goldman D, Montesinos I, Zaytouni S, et al. Presence
539 of Cytomegalovirus in urine and blood of pregnant women with primary infection might be
540 associated with fetal infection. J Clin Virol. 2017;90: 14–17.
541 doi:https://dx.doi.org/10.1016/j.jcv.2017.03.004
542 11. Gabrielli L, Bonasoni MP, Lazzarotto T, Lega S, Santini D, Foschini MP, et al. Histological
543 findings in foetuses congenitally infected by cytomegalovirus. J Clin Virol. 2009;46.
544 doi:10.1016/j.jcv.2009.09.026
545 12. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. Extensive Genome-Wide
546 Variability of Human Cytomegalovirus in Congenitally Infected Infants. PLoS Pathog.
547 2011;7. doi:10.1371/journal.ppat.1001344
548 13. Renzette N, Gibson L, Bhattacharjee B, Fisher D, Schleiss MR, Jensen JD, et al. Rapid
549 Intrahost Evolution of Human Cytomegalovirus Is Shaped by Demography and Positive
550 Selection. PLoS Genet. 2013; doi:10.1371/journal.pgen.1003735
551 14. Lassalle F, Depledge DP, Reeves MB, Brown AC, Christiansen MT, Tutill HJ, et al.
552 Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of
553 human cytomegalovirus genomes. Virus Evol. 2016;2: vew017. doi:10.1093/ve/vew017
554 15. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, et al.
555 Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci.
556 2015;112: E4120–E4128. doi:10.1073/pnas.1501880112
557 16. Cudini J, Roy S, Houldcroft CJ, Bryant JM, Depledge DP, Tutill H, et al. Human
558 cytomegalovirus haplotype reconstruction reveals high diversity due to superinfection and
559 evidence of within-host recombination. Proc Natl Acad Sci. 2019;116: 201818130.
560 doi:10.1073/pnas.1818130116
561 17. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. Deep Sequencing Reveals
562 Highly Complex Dynamics of Human Cytomegalovirus Genotypes in Transplant Patients
563 over Time. J Virol. 2010;84: 7195–7203. doi:10.1128/JVI.00475-10

564 18. Ross SA, Novak Z, Pati S, Patro RK, Blumenthal J, Danthuluri VR, et al. Mixed infection
565 and strain diversity in congenital cytomegalovirus infection. J Infect Dis. 2011;204: 1003–
566 1007. doi:10.1093/infdis/jir457
567 19. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and
568 evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol. 1995;247:
569 443–58. doi:10.1006/jmbi.1995.0152
570 20. Deere JD, Barry PA. Using the nonhuman primate model of HCMV to guide vaccine
571 development. Viruses. 2014;6: 1483–1501. doi:10.3390/v6041483
572 21. Itell HL, Kaur A, Deere JD, Barry PA, Permar SR. Rhesus monkeys for a nonhuman
573 primate model of cytomegalovirus infections. Curr Opin Virol. The Authors; 2017;25: 126–
574 133. doi:10.1016/j.coviro.2017.08.005
575 22. dela Pena MG, Strelow L, Barry PA, Abel K. Use of specific-pathogen-free (SPF) rhesus
576 macaques to better model oral pediatric cytomegalovirus infection. J Med Primatol.
577 2012;41: 225–229. doi:10.1111/j.1600-0684.2012.00541.x
578 23. Bialas KM, Tanaka T, Tran D, Varner V, Cisneros De La Rosa E, Chiuppesi F, et al.
579 Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a
580 novel nonhuman primate model of placental cytomegalovirus transmission. Proc Natl
581 Acad Sci U S A. 2015;112: 13645–50. doi:10.1073/pnas.1511526112
582 24. Hansen SG, Strelow LI, Franchi DC, David G, Wong SW, Anders DG. Complete
583 Sequence and Genomic Analysis of Rhesus Cytomegalovirus Complete Sequence and
584 Genomic Analysis of Rhesus Cytomegalovirus. J Virol. 2003;77: 6620–6636.
585 doi:10.1128/JVI.77.12.6620
586 25. Assaf BT, Mansfield KG, Strelow L, Westmoreland S V., Barry PA, Kaur A. Limited
587 Dissemination and Shedding of the UL128 Complex-Intact, UL/b'-Defective Rhesus
588 Cytomegalovirus Strain 180.92. J Virol. 2014;88: 9310–9320. doi:10.1128/JVI.00162-14
589 26. Rivailler P, Kaur A, Johnson RP, Wang F. Genomic sequence of rhesus cytomegalovirus

590 180.92: insights into the coding potential of rhesus cytomegalovirus. J Virol. 2006;80:
591 4179–82. doi:10.1128/JVI.80.8.4179-4182.2006
592 27. Oxford KL, Strelow L, Yue Y, Chang WLW, Schmidt KA, Diamond DJ, et al. Open
593 Reading Frames Carried on UL/b' Are Implicated in Shedding and Horizontal
594 Transmission of Rhesus Cytomegalovirus in Rhesus Monkeys. J Virol. 2011;85: 5105–
595 5114. doi:10.1128/JVI.02631-10
596 28. National Research Council of the National Academies. Guide for the care and use of
597 laboratory animals [Internet]. Eighth edi. Washington, D.C.: National Academies press;
598 2011. doi:10.1163/1573-3912_islam_DUM_3825
599 29. Zhang J, Kobert K, Flouri T, Stamatakis A. PEAR: a fast and accurate Illumina Paired-
600 End reAd mergeR. Bioinformatics. Oxford University Press; 2014;30: 614.
601 doi:10.1093/bioinformatics/btt593
602 30. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: Single-base resolution de
603 novo clustering for amplicon deep sequencing. Nucleic Acids Res. Oxford University
604 Press; 2018;46: 1–13. doi:10.1093/nar/gkx1201
605 31. Nelson CW, Hughes AL. Within-host nucleotide diversity of virus populations: Insights
606 from next-generation sequencing. Infect Genet Evol. Elsevier B.V.; 2015;30: 1–7.
607 doi:10.1016/j.meegid.2014.11.026
608 32. Renzette N, Pfeifer SP, Matuszewski S, Kowalik TF, Jensen JD. On the Analysis of
609 Intrahost and Interhost Viral Populations: Human Cytomegalovirus as a Case Study of
610 Pitfalls and Expectations. J Virol. 2017;91: e01976-16. doi:10.1128/JVI.01976-16
611 33. Sackman A, Pfeifer S, Kowalik TF, Jensen J. On the Demographic and Selective Forces
612 Shaping Patterns of Human Cytomegalovirus Variation within Hosts. Pathogens. 2018;7:
613 16. doi:10.3390/pathogens7010016
614 34. Pereira L, Petitt M, Fong A, Tsuge M, Tabata T, Fang-Hoonver J, et al. Intrauterine
615 growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis.

616 2014;209: 1573–1584. doi:10.1093/infdis/jiu019
617 35. Pokalyuk C, Renzette N, Irwin KK, Pfeifer SP, Gibson L, Britt WJ, et al. Characterizing
618 human cytomegalovirus reinfection in congenitally infected infants: an evolutionary
619 perspective. Mol Ecol. 2017;26: 1980–1990. doi:10.1111/mec.13953
620 36. Renzette N, Gibson L, Jensen JD, Kowalik TF. Human cytomegalovirus intrahost
621 evolution - A new avenue for understanding and controlling herpesvirus infections. Curr
622 Opin Virol. Elsevier B.V.; 2014;8: 109–115. doi:10.1016/j.coviro.2014.08.001
623 37. Kadambari S, Atkinson C, Luck S, Macartney M, Conibear T, Harrison I, et al.
624 Characterising Variation in Five Genetic Loci of Cytomegalovirus During Treatment for
625 Congenital Infection. J Med Virol. 2017;89: 503–507. doi:10.1002/jmv.24654
626 38. Choi KY, Root M, McGregor A. A Novel Non-Replication-Competent Cytomegalovirus
627 Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection. J Virol.
628 2016;90: 7902–7919. doi:10.1128/JVI.00283-16
629 39. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine
630 prevention of maternal cytomegalovirus infection. Obstet Gynecol Surv. 2009;64: 502–
631 504. doi:10.1097/01.ogx.0000356753.12837.a8
632 40. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety
633 and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A
634 randomized clinical trial. Vaccine. Elsevier Ltd; 2016;34: 313–319.
635 doi:10.1016/j.vaccine.2015.11.056
636

637 **Figure legends**

638

639 **Figure 1. UCD52 haplotype networks for the *gB* locus across sampled tissues from three**
640 **representative monkeys.** Haplotype networks are shown for one control group dam (A), one
641 standard pretreatment group dam (B), and one high-potency pretreatment group dam (C). Edges
642 connect haplotypes that differ by a single nucleotide, with green edges depicting synonymous
643 mutations and red edges depicting nonsynonymous mutations. Node sizes scale with haplotype
644 relative frequency. Samples are labeled by collection week. Blue lines connect shared haplotypes
645 across samples.

646

647 **Figure 2. The number of UCD52 minor *gB* haplotypes that are either shared or unique**
648 **across compartments, by monkey.** Here, the set of minor haplotypes for a given compartment
649 includes all timepoint samples from that compartment. Patterns of minor haplotype sharing for (A)
650 control group monkeys, (B) standard pretreatment group monkeys, and (C) high-potency
651 pretreatment group monkeys. Compartments are color-coded as in Figure 1.

652

653 **Figure 3. Median number of minor haplotypes, by locus, tissue, and pretreatment group.**
654 The left column shows the median number of *gB* minor haplotypes; the right column shows the
655 median number of *gL* minor haplotypes. Rows show tissues: plasma, amniotic fluid, saliva, and
656 urine. Marker symbols correspond with those in Figure S2.

657

658 **Figure 4. Pairwise genetic diversity π over time, by tissue, for the *gB* locus.** Marker symbols
659 correspond with those in Figure S2.

660

661 **Figure 5**. **Minor UCD52 haplotypes found in fetal tissues, and their presence in maternal**
662 **compartments of dam S3.** Each row depicts a haplotype found in at least one fetal tissue

663 (purple), harvested at 6 weeks post-RhCMV infection. Rows are ordered from highest frequency
664 haplotype (bottom row) to lowest frequency haplotype (top row).
665
666
667 **Supplementary figures legends**
668
669 **Figure S1**. The use of synthetic plasmids to define a frequency threshold to exclude spurious
670 haplotypes from samples. Minor haplotypes were identified from the synthetic plasmid control
671 samples as described in the Methods section, for both the *gB* locus and the *gL* locus. The figure
672 shows, for each locus, the fraction of identified minor haplotypes (y-axis) that fall at the haplotype
673 frequency shown on the x-axis or below. The vertical red line shows the frequency threshold of
674 0.436% that was used to call minor haplotypes.
675
676 **Figure S2. Viral load dynamics measured in dams experimentally infected with RhCMV**.
677 Virus was measured in (A) plasma, (B) amniotic fluid, (C) saliva, and (D) urine. Monkeys are color-
678 coded according to pretreatment group: control (black), standard pretreatment group (red), and
679 high-potency pretreatment group (blue). Monkey ID numbers correspond to those provided in
680 Table S1. Virus was detected in the plasma, saliva, and urine of all 11 monkeys. Virus was only
681 detected in the amniotic fluid of the 5 control group monkeys and in 2 of the 3 standard HIG group
682 monkeys. Viral load levels shown here are average values when more than one measurement
683 was available (Methods).
684
685 **Figure S3**. **Strain composition of the RhCMV population in various maternal compartments**
686 **over time.** The proportion of the RhCMV population belonging to strain UCD52 is shown for
687 maternal plasma, saliva, and urine. Strain frequencies were calculated for the *gB* locus (left
688 column) and for the *gL* locus (right column). Green squares in the plasma subplots denote the

689 fraction of the viral inoculum that was UCD52 (25%).

690

691 **Figure S4 – S11. Haplotype networks for the *gB* locus across sampled tissues from the**
692 **remaining 8 monkeys in the study.** Colorcoding of nodes and edges are as in Figure 1, which
693 show haplotype networks for C4, S2, and HP3. Figures S4-S7 are for monkeys C1, C2, C3, C5,
694 respectively. Figures S8-9 are for monkeys S1 and S3 respectively. Figures S10-S11 are for
695 monkeys HP1 and HP2, respectively.

696

697 **Figure S12**. **The relationship between viral load and the number of *gB* haplotypes found in**
698 **each sample**. The correlation between viral load and the number of *gB* haplotypes was not
699 significantly positive for any of the four analyzed compartments (plasma, amniotic fluid, saliva,
700 urine).

701

702 **Figure S13 – S22. Haplotype networks for the *gL* locus across sampled tissues from each**
703 **of the 10 monkeys in the study that had at least one successfully sequenced *gL* sample.**
704 Colorcoding of nodes and edges are as in Figure 1. Figures S13-S16 are for monkeys C1, C3,
705 C4, and C5, respectively (monkey C2 did not have a successfully sequenced *gL* sample). Figures
706 S17-S19 are for monkeys S1-S3 respectively. Figures S20-S22 are for monkeys HP1-HP3
707 respectively.

708

709 **Figure S23**. **The relationship between viral load and the number of *gL* haplotypes found in**
710 **each sample**. The correlation between viral load and the number of *gL* haplotypes was not
711 significantly positive for any of the four analyzed compartments (plasma, amniotic fluid, saliva,
712 urine).

713

714 **Figure S24. The number of UCD52 minor *gL* haplotypes that are either shared or unique**

715 **across compartments, by monkey.** Here, the set of minor haplotypes for a given compartment
716 includes all timepoint samples from that compartment. Patterns of minor haplotype sharing for (A)
717 control group monkeys, (B) standard pretreatment group monkeys, and (C) high-potency
718 pretreatment group monkeys. Compartments are colorcoded as in Figure 1.
719
720 **Figure S25. Pairwise genetic diversity π over time, by tissue, for the *gL* locus.** Marker
721 symbols correspond with those in Figure S2.
722
723 **Supplementary tables**
724
725 **Table S1. Sampling times and tissues across the 11 studied dams.** Dams are separated by
726 pretreatment group: control (C1-C5), standard (S1-S3), and high-potency (HP1-HP3). In
727 addition to the C1-C5, S1-S3, and HP1-HP3 identifiers, individual monkeys are identified
728 according to names previously used in [9] and [23]. Cells are colored according to the legend
729 provided. Text in the white-colored cells indicate which loci were successfully sequenced and
730 included in our analyses (*gB* = glycoprotein B region; *gL* = glycoprotein L region). Numbers in
731 the cells, when present, indicate the number of sample replicates that were available for
732 analysis, when not two.
733
734 **Table S2. Fetal-maternal interface and fetal tissues analyzed in the study.** All listed
735 samples had two successfully sequenced replicates.
736
737 **Supplementary appendices**
738 **Appendix S1. Haplotypes information at *gB* locus.** List of all unique haplotypes identified in all
739 the monkeys and viral stocks at the *gB* locus, including the number and type of mutations as
740 compared to their respective strain reference.

741 **Appendix S2. Haplotypes information at *gL* locus.** List of all unique haplotypes identified in all
742 the monkeys and viral stocks at the *gL* locus, including the number and type of mutations as
743 compared to their respective strain reference.
744
745 **Appendix S3. Haplotypes per sample at *gB* locus.** Table containing all the haplotypes found
746 in each sample at the *gB* locus. Samples are defined by the monkey ID, tissue of origin and
747 collection week post-RhCMV infection. Each haplotype entry includes its reference strain and
748 relative frequency in a given sample.
749
750 **Appendix S4. Haplotypes per sample at *gL* locus.** Table containing all the haplotypes found in
751 each sample at the *gL* locus. Samples are defined by the monkey ID, tissue of origin and collection
752 week post-RhCMV infection. Each haplotype entry includes its reference strain and relative
753 frequency in a given sample.

Figure 1


Control
C4
W2
W4
W5
W6
UCD52
W1
W2
W3
W4
W5
Placenta
W5
W6
Placenta
W2
AF
membrane
Standard
S2
W2
W4
W6
UCD52
W1
W2
W3
W4
W5
W6
W6
Placenta
Placenta
Placenta
Plasma
W2
W5
High-potency
HP3
W4
W6
W7
W8
UCD52
W2
W3
W4
W7
W9
W10
Tissue
Inoculum
Plasma
Saliva
Urine
Placenta
Fetal
Amniotic
fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure 2


Compartment
Plasma
Amniotic fluid
Saliva
Urine
Placenta
Fetal tissues
A
Control
C1
2
1
C2
7
5
C3
6
2
48
C4
4
2
1
10
2
3
6
C5
11
1
7
4
2
2
1
5
B
Standard
S1
2
1
1
22
1
7
S2
21
6
3
6
1
13
0
S3
36
1
3
3
1
1
1
4
1
19
1
1
3
12
1
C
High-potency
HP1
6
4
12
1
8
HP2
11
1
2
3
HP3
7
6
4
2

Figure 3


gB
gL
A
B
C
D
E
F
G
H
Plasma
Amniotic fluid
Saliva
Urine
Median number of minor haplotypes
0
5
10
C1 C2 C3 C4 C5 S1 S2 S3 HP1 HP2 HP3
Monkey
Pretreatment group
Control
Standard
High−potency

Figure 4


Plasma
Amniotic fluid
Saliva
Urine
Nucleotide diversity
0.003
0.002
0.001
0.000
3
6
9
Week post−RhCMV infection
Pretreatment group
Control
Standard
High−potency
Monkey
1
2
3
4
5

Figure 5


Fetal
Amniotic fluid
Plasma
Saliva
UCD52 Haplotypes
C145T
G316A
T302C
T258C
T173C
G161A
T153C
T51G
T28C
A84G
A91G
A170G
T305C
T251C
T133C
T49C
A1G
A36G
A128G
A2G
T243C
T237C
Major
Lung
AF−membrane
Spleen
Brain−parietal
Heart
Kidney
Placenta
W2
W3
W5
W3
W5
W6
W5

Figure S1


1.00
0.75
0.50
0.25
0.00
Cumulative proportion of minor haplotypes
0
0.2
0.4
0.6
Haplotype frequency (%)
0.436%
Locus
gB
gL

Figure S2


Monkey 1 2 3 4 5
Pretreatment group Control Standard High−potency
A Plasma
B Amniotic fluid
C Saliva
D Urine
Viral load
log10 (RhCMV copies/mL)
log10 (RhCMV copies/mg of DNA)
Week post−RhCMV infection

Figure S3


Monkey
1
2
3
4
5
Pretreatment group
Control
Standard
High−potency
gB
gL
Plasma
Saliva
Urine
UCD52 frequency
1.00
0.75
0.50
0.25
0.00
0
2
4
6
8
10
Week post−RhCMV infection

Figure S4


UCD52
W1
W3
C1
Tissue
Inoculum
Plasma
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared


Figure S5
UCD52
W1
W3
W3
C2
Tissue
Inoculum
Plasma
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared


Figure S6
UCD52
W1
W2
W3
W5
W7
W9
C3
W1
Haplotype type
Synonymous
Non synonymous
Shared
Tissue
Inoculum
Plasma
Amniotic fluid

Figure S7


C5
W2
W5
W6
W8
UCD52
W1
W2
W3
W4
W5
W6
W3
W5
W6
W7
W8
W10
W3
Tissue
Inoculum
Plasma
Saliva
Urine
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S8


S1
W2
W4
W5
W6
UCD52
W2
W5
W6
W6
Tissue
Inoculum
Plasma
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S9


S3
W3
W4
W5
W6
UCD52
W1
W2
W3
W4
W5
W6
W5
W6
Placenta
AF membrane
W2
W3
W5
W6
Brain parietal
Heart
Kidney
Lung
Spleen
Tissue
Inoculum
Plasma
Saliva
Urine
Placenta
Fetal
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S10


HP1
UCD52
W2
W3
W4
W5
W6
W6
W7
W8
W9
W10
W11
W8
W10
Tissue
Inoculum
Plasma
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S11


HP2
UCD52
W3
W5
W6
W7
W8
W9
W10
W11
W4
W5
W6
W8
W9
W10
Tissue
Inoculum
Plasma
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S12


Monkey
1
2
3
4
5
Pretreatment group
Control
Standard
High−potency
Plasma
Amniotic fluid
Saliva
Urine
Viral load
log10 (RhCMV copies/mL)
log10 (RhCMV copies/mg of DNA)
Number of haplotypes

Figure S13


UCD52
W1
C1
Tissue
Inoculum
Plasma
Haplotype type
Synonymous
Non synonymous
Shared

Figure S14


UCD52
W1
W3
W5
W7
W1
C3
Tissue
Inoculum
Plasma
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S15


C4
W2
W3
W4
W5
W6
UCD52
W3
W4
W4
W5
W6
Placenta
Placenta
W2
AF membrane
Tissue
Inoculum
Plasma
Saliva
Urine
Placenta
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S16


W2
W3
W5
W6
W8
UCD52
W2
W3
W4
W3
W5
W6
W7
W8
W9
C5
Tissue
Inoculum
Plasma
Saliva
Urine
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S17


UCD52
W2
W4
W5
W6
W6
S1
Tissue
Inoculum
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S18


S2
W4
W6
UCD52
W2
W3
W4
W5
W6
Placenta
Placenta
Placenta plasma
W2
W5
W6
Tissue
Inoculum
Plasma
Saliva
Urine
Placenta
Amniotic fluid
Haplotype type
Synonymous
Non synonymous
Shared

Figure S19



S3

Figure S20


UCD52
W4
W6
W7
W9
W10
W11
W2
W4
W9
HP1
Tissue
Inoculum
Plasma
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S21


W3
W5
W6
W7
W8
W9
W10
W11
UCD52
HP2
W8
W9
W10
Tissue
Inoculum
Plasma
Saliva
Urine
Haplotype type
Synonymous
Non synonymous
Shared

Figure S22



Tissue

- Inoculum
- Plasma
- Saliva
- Urine

Haplotype type

- Synonymous
- Non synonymous
- Shared

Figure S23


Monkey
1
2
3
4
5
Pretreatment group
Control
Standard
High−potency
Plasma
Amniotic fluid
Saliva
Urine
Viral load
log10 (RhCMV copies/mL)
log10 (RhCMV copies/mg of DNA)
Number of haplotypes

Figure S24


Compartment
Plasma
Amniotic fluid
Saliva
Urine
Fetal tissues
A
Control
C3
26
1
6
C4
15
6
1
2
13
1
4
1
11
6
C5
11
3
1
1
9
1
1
9
3
B
Standard
S1
4
1
13
S2
32
1
0
1
1
2
7
0
33
S3
7
2
7
C
High-potency
HP1
7
2
8
1
1
HP2
7
8
4
HP3
2
1
4
1
14

Figure S25


Plasma
Amniotic fluid
Saliva
Urine
Nucleotide diversity
0.000
0.001
0.002
0.003
0.004
3
6
9
Week post−RhCMV infection
Pretreatment group
Control
Standard
High−potency
Monkey
1
2
3
4
5

Pretreatment group	Monkey	Tissue	Week post-RhCMV infection										
			1	2	3	4	5	6	7	8	9	10	11
Control	C1 (145-97)	Plasma	gB(1),gL(4)	neither				neither					
		Amn. fluid			gB								
	C2 (174-97)	Plasma	gB(1)	neither	gB(4)								
		Amn. fluid			gB								
	C3 (369-09)	Plasma	gB,gL	gB	gB,gL		gB,gL		gB(3),gL		gB		neither
		Amn. fluid	gB,gL										
	C4 (GM04)	Plasma	gB	gB	gB,gL	gB,gL	gB(1)						
		Amn. fluid		gB,gL	gL								
		Saliva				gL(1)	gB,gL	gB,gL					
		Urine		gB,gL	gL	gB,gL	gB,gL	gB,gL					
	C5 (HD79)	Plasma	gB	gB,gL	gB,gL	gB,gL	gB	gB					
		Amn. fluid			gB(3),gL								
		Saliva			gB		gB,gL	gB,gL	gB,gL	gB,gL	gL	gB	
		Urine		gB,gL	gL		gB,gL	gB,gL		gB,gL			
Standard	S1 (JC65)	Plasma	neither	gB	neither	gB	gB	gB(3)					
		Saliva						gB(4),gL(4)					
		Urine		gB,gL		gB,gL	gB,gL	gB,gL					
	S2 (GI73)	Plasma	gB	gB(4),gL(1)	gB(3),gL(1)	gB,gL	gB,gL	gB					
		Amn. fluid		gB,gL		neither	gB,gL	gL					
		Saliva						gB,gL					
		Urine		gB		gB,gL		gB,gL					
	S3 (IM67)	Plasma	gB	gB(4)	gB(4)	gB	gB	gB					
		Amn. fluid		gB,gL	gB	neither	gB	gB					
		Saliva				neither	gB	gB					
		Urine		neither	gB	gB,gL	gB,gL	gB,gL					
High-potency	HP1 (JM52)	Plasma		gB,gL	gB(3)	gB,gL	gB	gB					
		Saliva								gB	gL	gB	
		Urine				gL		gB,gL	gB,gL	gB	gB,gL	gB,gL	gB,gL
	HP2 (HR73)	Plasma		neither	neither	gB	gB	gB					
		Saliva				neither				gB,gL	gB,gL	gB,gL	neither
		Urine			gB,gL		gB,gL	gB,gL	gB,gL	gB,gL	gB,gL	gB,gL	gB,gL
	HP3 (HD82)	Plasma		gB	gB,gL	gB	neither	neither					
		Saliva					neither		gB,gL		gB	gB,gL	
		Urine				gB,gL	neither	gB,gL	gB	gB,gL	gL	gL	

Sample not taken
Sample depleted
Sample not sequenced due to low viral load
Failed PCR amplification

Pretreatment group	Monkey	Tissue	Week	Samples
Control	C4	Amn. fluid membrane	3	gB, gL
		Placenta -1	3	gB, gL
		Placenta -2	3	gB, gL
Standard	S2	Placenta - 1	6	gB, gL
		Placenta - 2	6	gB, gL
		Placenta plasma	6	gB, gL
	S3	Amn. fluid membrane	6	gB
		Placenta - 2	6	gB
		Lung	6	gB
		Brain - parietal	6	gB
		Spleen	6	gB
		Heart	6	gB
		Kidney	6	gB